Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

OSLO, Norway, Aug. 5, 2025 /PRNewswire/ — Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application…